DF02 enters Phase I
Having completed toxicology studies, DF02 will now enter Phase I studies in May 2009. Single and multiple doses will be administered in man for the first time to secure the safety of the pharmaceutical. The Phase I trial will be followed by a Phase II Proof of Concept in "Severe Malaria". This is estimated to be initiated in Q I-II 2010.